Evidence map›Paper›PMID 27280620›Full record

ArticleClinical and vaccine immunology : CVI2016

Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination.

Lori Garman, Kenneth Smith, Emily E Muns, Cathy A Velte, Christina E Spooner, Melissa E Munroe, A Darise Farris, Michael R Nelson, Renata J M Engler, Judith A James

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lori GarmanOklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, Oklahoma, USA Oklahoma University Health Science Center, Department of Microbiology and Immunology, Oklahoma City, Oklahoma, USA.
Kenneth SmithOklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, Oklahoma, USA.
Emily E MunsOklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, Oklahoma, USA.
Cathy A VelteOklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, Oklahoma, USA.
Christina E SpoonerWalter Reed National Military Medical Center, Bethesda, Maryland, USA.
Melissa E MunroeOklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, Oklahoma, USA.
A Darise FarrisOklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, Oklahoma, USA Oklahoma University Health Science Center, Department of Microbiology and Immunology, Oklahoma City, Oklahoma, USA.
Michael R NelsonWalter Reed National Military Medical Center, Bethesda, Maryland, USA.
Renata J M EnglerWalter Reed National Military Medical Center, Bethesda, Maryland, USA.
Judith A JamesOklahoma Medical Research Foundation, Department of Arthritis and Clinical Immunology, Oklahoma City, Oklahoma, USA Oklahoma University Health Science Center, Department of Microbiology and Immunology, Oklahoma City, Oklahoma, USA Oklahoma University Health Science Center, Departments of Medicine and Pathology, Oklahoma City, Oklahoma, USA jamesj@omrf.org.
Oklahoma Medical Research Foundation · USWalter Reed National Military Medical Center · USUniversity of Oklahoma Health Sciences Center · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2M
Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA F · 2004 to 2023
$56.2M
Molecular Basis of Immunity - Kirschtein-NRSAT32AI007633 · NIAID · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CUNNINGHAM, MADELEINE W. · 2001 to 2022
$4.0M
Science in a Culture of MentoringP30GM103510 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$3.9M
NIAID NIH HHS T32 AI007633NIAID NIH HHS U19 AI062629NIGMS NIH HHS P30 GM103510NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

Although the U.S. National Academy of Sciences concluded that anthrax vaccine adsorbed (AVA) has an adverse event (AE) profile similar to those of other adult vaccines, 30 to 70% of queried AVA vaccinees report AEs. AEs appear to be correlated with certain demographic factors, but the underlying immunologic pathways are poorly understood. We evaluated a cohort of 2,421 AVA vaccinees and found 153 (6.3%) reported an AE. Females were more likely to experience AEs (odds ratio [OR] = 6.0 [95% confidence interval {CI} = 4.2 to 8.7]; P < 0.0001). Individuals 18 to 29 years of age were less likely to report an AE than individuals aged 30 years or older (OR = 0.31 [95% CI = 0.22 to 0.43]; P < 0.0001). No significant effects were observed for African, European, Hispanic, American Indian, or Asian ancestry after correcting for age and sex. Additionally, 103 AEs were large local reactions (LLRs), whereas 53 AEs were systemic reactions (SRs). In a subset of our cohort vaccinated 2 to 12 months prior to plasma sample collection (n = 75), individuals with LLRs (n = 33) had higher protective-antigen (PA)-specific IgE levels than matched, unaffected vaccinated individuals (n = 50; P < 0.01). Anti-PA IgE was not associated with total plasma IgE, hepatitis B-specific IgE, or anti-PA IgG in individuals who reported an AE or in matched, unaffected AVA-vaccinated individuals. IP-10 was also elevated in sera of individuals who developed LLRs (P < 0.05). Individuals reporting SRs had higher levels of systemic inflammation as measured from C-reactive protein (P < 0.01). Thus, LLRs and SRs are mediated by distinct pathways. LLRs are associated with a vaccine-specific IgE response and IP-10, whereas SRs demonstrate increased systemic inflammation without a skewed cytokine profile.

Indexed as

AdolescentAdultAge FactorsAnthrax VaccinesAntibodies, BacterialAntigens, BacterialBacterial ToxinsChemokine CXCL10C-Reactive ProteinDrug-Related Side Effects and Adverse ReactionsEthnicityFemaleHumansImmunoglobulin EMaleMiddle Agedanthrax toxinAnthrax VaccinesAntibodies, BacterialAntigens, BacterialBacterial ToxinsChemokine CXCL10C-Reactive ProteinCXCL10 protein, humanImmunoglobulin E

Identifiers

PMID27280620
PMCPMC4979178
OpenAlexW2501700629

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.